Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia

• Published in: Journal of clinical oncology Vol. 36; no. 18; pp. 1788 - 1797
• Main Authors: Morita, Kiyomi, Kantarjian, Hagop M., Wang, Feng, Yan, Yuanqing, Bueso-Ramos, Carlos, Sasaki, Koji, Issa, Ghayas C., Wang, Sa, Jorgensen, Jeffrey, Song, Xingzhi, Zhang, Jianhua, Tippen, Samantha, Thornton, Rebecca, Coyle, Marcus, Little, Latasha, Gumbs, Curtis, Pemmaraju, Naveen, Daver, Naval, DiNardo, Courtney D., Konopleva, Marina, Andreeff, Michael, Ravandi, Farhad, Cortes, Jorge E., Kadia, Tapan, Jabbour, Elias, Garcia-Manero, Guillermo, Patel, Keyur P., Futreal, P. Andrew, Takahashi, Koichi
• Format: Journal Article
• Language: English
• Published: United States American Society of Clinical Oncology 20.06.2018
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Clinical Trials, Phase II as Topic; Clofarabine - administration & dosage; Cohort Studies; Cytarabine - administration & dosage; DNA, Neoplasm - genetics; Female; High-Throughput Nucleotide Sequencing - methods; Humans; Idarubicin - administration & dosage; Induction Chemotherapy; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - mortality; Male; Middle Aged; Mutation; RAPID COMMUNICATION; Recurrence; Sequence Analysis, DNA - methods; Vidarabine - administration & dosage; Vidarabine - analogs & derivatives

Purpose The aim of the current study was to determine whether the degree of mutation clearance at remission predicts the risk of relapse in patients with acute myeloid leukemia (AML). Patients and Methods One hundred thirty-one previously untreated patients with AML who received intensive induction...